甲状腺疾病对心房颤动患者的影响：来自JoFib注册研究的分析。
Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry.
作者信息
Al-Makhamreh Hanna, Al-Ani Abdallah, Alkhulaifat Dana, Shaban Liza, Salah Neveen, Almarayaty Rusul, Al-Huneidy Yazan, Hammoudeh Ayman
机构信息
Department of Internal Medicine, Division of Cardiology, Jordanian University Hospital, Amman, 11185, Jordan.
University of Jordan, School of Medicine, Amman, 11185, Jordan.
出版信息
Ann Med Surg (Lond). 2022 Jan 29;74:103325. doi: 10.1016/j.amsu.2022.103325. eCollection 2022 Feb.
BACKGROUND
Thyroid disease is a well-established risk factor for atrial fibrillation (AF). However, only a handful of studies examined its impact on treatment. This study aims to report the prevalence rate of thyroid disease in patients with AF and to demonstrate the effect of thyroid disease on AF treatment.
MATERIALS AND METHODS
We retrospectively analyzed the Jordanian Atrial Fibrillation Study (JoFib). Among Jordan and Palestine, patients with AF were evaluated for their sociodemographic, clinical, and pharmacological characteristics.
RESULTS
A total of 2000 patients with AF (53.3% males, mean age 67.6 ± 13.1 years) were enrolled in the JoFib registry from May 2019 to November 2020. Thyroid disease was present in 210 (10.5%) patients. Hypertension, diabetes mellitus, and dyslipidemia were the most common comorbidities among patients with thyroid history (75.2%, 51.0%, and 45.7%, respectively). Diabetes mellitus ( = .04), pulmonary hypertension ( = .01), and chronic kidney disease ( = .01) were significantly higher in this particular subgroup. Patients with thyroid disease demonstrated significantly higher usage of anticoagulants ( = .02).
CONCLUSION
Despite having similar stroke and bleeding risks, patients with thyroid disease demonstrated meaningful differences in their baseline characteristics. Prospective studies are required to assess the influence of thyroid hormone fluctuations on the progression of AF.
背景
甲状腺疾病是心房颤动（AF）公认的危险因素。然而，仅有少数研究考察了其对治疗的影响。本研究旨在报告AF患者中甲状腺疾病的患病率，并阐明甲状腺疾病对AF治疗的影响。
材料与方法
我们回顾性分析了约旦心房颤动研究（JoFib）。在约旦和巴勒斯坦，对AF患者的社会人口统计学、临床和药理学特征进行了评估。
结果
2019年5月至2020年11月，共有2000例AF患者（男性占53.3%，平均年龄67.6±13.1岁）纳入JoFib登记系统。210例（10.5%）患者存在甲状腺疾病。有甲状腺病史的患者中，高血压、糖尿病和血脂异常是最常见的合并症（分别为75.2%、51.0%和45.7%）。在这个特定亚组中，糖尿病（P = .04）、肺动脉高压（P = .01）和慢性肾脏病（P = .01）的患病率显著更高。甲状腺疾病患者使用抗凝剂的比例显著更高（P = .02）。
结论
尽管甲状腺疾病患者的中风和出血风险相似，但其基线特征存在显著差异。需要进行前瞻性研究来评估甲状腺激素波动对AF进展的影响。
Zotero 插件